[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[C:12]4[CH:31]=[CH:30][N:29](S(C5C=CC(C)=CC=5)(=O)=O)[C:13]=4[N:14]=[C:15]([NH:17][C:18]4[CH:23]=[CH:22][C:21]([N:24]([CH3:28])[C:25](=[O:27])[CH3:26])=[CH:20][CH:19]=4)[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1.[OH-].[K+]>CO>[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[C:12]4[CH:31]=[CH:30][NH:29][C:13]=4[N:14]=[C:15]([NH:17][C:18]4[CH:19]=[CH:20][C:21]([N:24]([CH3:28])[C:25](=[O:27])[CH3:26])=[CH:22][CH:23]=4)[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1To a solution of N-(4-(4-(1H-indazol-6-ylamino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)-N-methylacetamide (45 mg, 0.080 mmol) in methanol (MeOH) (3 mL), aq. 1N potassium hydroxide (KOH) (0.50 mL, 0.50 mmol) was added. The mixture was then heated at 60° C. for 4 h before it was concentrated in vacuo. The residue was then acidified with acetic acid (HOAc) (0.5 mL) before being purified by HPLC to give the title compound (20 mg). MS 413.1 (M+H) (Compound 6-1).